As previously reported, Guggenheim analyst Seamus Fernandez downgraded Eli Lilly (LLY) to Neutral from Buy, stating that while he expects updates at the American Diabetes Association meeting to be broadly positive, he sees limited upside for the stock from current levels until Lilly’s overall immunology portfolio and competition from Novo Nordisk’s (NVO) semaglutide franchise is more fully understood. Though he still thinks Eli Lilly has “the best long-term growth profile in US Pharma,” that growth is the broad consensus view, said Fernandez, who removed his price target on the stock but estimates the fair value to be in the range of $125-$135 per share.
https://thefly.com/landingPageNews.php?id=2891267
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.